Tectonic Therapeutic, Inc. (NASDAQ: TECX) reported that single ascending doses of TX2100 were generally safe and well-tolerated in a Phase 1a clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to TX2100 for Hereditary Hemorrhagic Telangiectasia (HHT) and cleared the Investigational New Drug application for the next phase of trials.
The Phase 1a trial evaluated 48 healthy adult volunteers. The company reported that the drug was generally safe and well-tolerated across all six planned dose cohorts. Treatment-emergent adverse events were mild or moderate and transient. There were no deaths, serious adverse events, or severe treatment-emergent adverse events at any dose level. The trial did not show clinically significant shifts in vital signs, lab values, or ECG readings. Anti-drug antibody results are pending.
Pharmacokinetic results reflected target-mediated drug disposition at low concentrations, confirming high affinity binding to the APJ receptor. Tectonic stated that dose selection for upcoming trials is informed by two independent methods: exposures associated with high receptor occupancy from the observed target-mediated drug disposition, and target exposure levels shown to drive activity in nonclinical models. These methods converged on a consistent target exposure range. The observed pharmacokinetic results support exploration of once weekly and every other week subcutaneous dosing regimens in future clinical trials.
| Trial Phase | Population | Status |
|---|---|---|
| Phase 1a | Healthy adult volunteers | Topline results announced |
| Phase 1b | HHT patients with hematologic support dependency | Planned initiation by year-end 2026 |
| Phase 2 | Moderate-to-severe HHT patients | Planned initiation in early 2027 |
Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic, described TX2100 as a potential first-in-class, selective anti-angiogenic therapy for HHT, a disease with no approved treatments. Marcella K. Ruddy, M.D., Chief Medical Officer of Tectonic Therapeutic, noted that the topline safety results are consistent with preclinical toxicology studies that demonstrated no dose limiting toxicities with wide safety margins.
Tectonic plans to initiate an open-label Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026. Endpoints for this trial will explore improvements in the need for iron and red blood cell support, as well as hematologic parameters. In parallel, the company plans to initiate a placebo-controlled Phase 2 clinical trial in patients with moderate-to-severe HHT in early 2027. Endpoints for the Phase 2 trial are expected to include epistaxis, hemoglobin, and hematologic support.
Detailed results from the Phase 1a trial, including safety, tolerability, pharmacokinetic, and anti-drug antibody data, will be presented at the CureHHT 16th HHT International Scientific Conference from October 12 to 16, 2026. The Phase 1a trial was conducted at CMAX Clinical Research in Adelaide, South Australia.